Incyte (INCY) Misses Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips below $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Incyte Reports 2018 First-Quarter Financial Results and Updates on Key Clinical Programs
May 1, 2018 7:00 AM EDTTotal product-related revenues of $382 million in Q1 2018, representing 30 percent growth over the same period last year; Jakafi® (ruxolitinib) revenues of $314 million in Q1 2018, representing 25 percent growth over the same period last year FDA Advisory Committee recommended approval of baricitinib 2mg for the treatment of moderately-to-severely active rheumatoid arthritis Management to highlight corporate growth and development portfolio in oncology and other indications at investor and analyst event on June 21, 2018
First-Quarter Conference Call and Webcast Scheduled Today at 8:00 a.m. ET
WILMINGTON,... More
